Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor

Authors

Zeni Kharel, Rochester Regional HealthFollow
Rajiv K. Pruthi, Division of Hematopathology, Comprehensive Hemophilia Center and Special Coagulation Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
Peter Kouides, Rochester Regional HealthFollow
Robin Reid, Rochester Regional HealthFollow

Department

Oncology and Hematology

Document Type

Article

Publication Title

Haemophilia

First Page

868

Last Page

871

DOI

10.1111/hae.15022

Volume

30

Issue

3

Publication Date

5-1-2024

Medical Subject Headings

Humans; Pregnancy; Female; Hemophilia A (drug therapy); Antibodies, Bispecific (therapeutic use, pharmacology); Antibodies, Monoclonal, Humanized (therapeutic use); Adult; Pregnancy Complications, Hematologic (drug therapy); Maternal-Fetal Exchange; Factor VIII (therapeutic use)

PubMed ID

38650315

Recommended Citation

Kharel, Z., Pruthi, R. K., Kouides, P., & Reid, R. (2024). Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Haemophilia, 30 (3), 868-871. https://doi.org/10.1111/hae.15022